Skip to main content

Table 1 Patient characteristics according to treatment group and response to preoperative DCS therapy evaluated by RECIST and histological evaluation criteria

From: Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study

Characteristic p-DCS group Control group
Number of patients 39 39
Age, yr.; median (range) 63.6 (30–78) 67.0 (41–80)
Gender Male 32 25
Female 7 14
ECOG performance status ≥1 2 0
0 37 39
Borrmann macroscopic type 1 0 1
2 14 10
3 21 16
4 1 10
5 3 2
Differentiation Diffuse 18 28
Intestinal 21 11
Clinical T stage cT0 0 0
cT1 0 0
cT2 5 5
cT3 13 16
cT4 21 18
Clinical N stage cN0 2 0
cN1 2 6
cN2 21 18
cN3 14 15
Clinical stage 0 0 0
I 0 0
II 0 0
III 13 38
IV 26 1
PAN metastasis (+) 16 0
(−) 23 0
Hepatic metastasis (+) 9 1
(−) 30 38
RECIST CR 0 -
PR 29 -
SD 8 -
PD 2 -
Histological evaluation criteria (Grade) 3 3 -
2 19 -
1b 4 -
1a 11 -
0 2 -
  1. CR complete response, DCS docetaxel, cisplatin, and S-1, ECOG Eastern Cooperative Oncology Group, PAN para-aortic lymph node, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria in Solid Tumors, SD stable disease